A new method for predicting crashworthiness.

Accid Anal Prev

University of North Carolina, Highway Safety Research Center, Chapel Hill 27599-3430, USA.

Published: January 1997

Consumer information concerning the predicted 'safeness' of a new car model is based on the results of crash tests. Unfortunately, because it allows comparisons only within size/weight groups, the information is somewhat incompatible with the normal car-purchase decision process since consumers often consider cars within different groups. In addition, based on past research, the association of the crash-test information with real-world crash outcomes is, at best, somewhat limited. The goal of this study was to explore a methodology for improving this information, a methodology which incorporates not only the crash-test information, but also information concerning real-world occupant injury experience in prior crashes involving similar vehicles ('clones'). The clone information included both driver injury severity in past clone crashes from the North Carolina accident file and various indicators of relative driver injury in clones extracted from published insurance-related data from the Highway Loss Data Institute (HLDI). Final models developed included both measures of the Head Index Criteria (HIC) from the crash test and some measure of clone performances as significant predictors. While the North Carolina clone data is intuitively 'cleaner' in that it describes injury level per crash rather than per insured year, the medical claims indices from the HLDI data consistently were shown to be the stronger predictors. Future research will need to look at ways of better combining the crash-test variables and of possible modifications to the HLDI indices. In general, the analyses generated encouraging results that appear to point to possible improvements in the crashworthiness information.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0001-4575(96)00052-8DOI Listing

Publication Analysis

Top Keywords

driver injury
8
north carolina
8
method predicting
4
predicting crashworthiness
4
crashworthiness consumer
4
consumer concerning
4
concerning predicted
4
predicted 'safeness'
4
'safeness' car
4
car model
4

Similar Publications

Background: Motor vehicle crashes are the second leading cause of injury death among adults aged 65 and older in the U.S., second only to falls.

View Article and Find Full Text PDF

Background And Aims: Alcohol-related liver disease (ALD) is one of the leading causes of severe liver disease with limited pharmacological treatments for alcohol-related steatohepatitis (ASH). CD44, a glycoprotein mainly expressed in immune cells, has been implicated in multiple inflammatory diseases but has never been studied in the ALD context. We therefore studied its contribution to ASH development in mice and its expression in ALD patients.

View Article and Find Full Text PDF

Objectives: The aims of the study were to identify the characteristics of medication-related malpractice claims occurring in the ambulatory setting across 2 time periods.

Methods: A retrospective, descriptive study was used. Ambulatory medication-related closed malpractice events from loss years of 2011-2021 were analyzed.

View Article and Find Full Text PDF

Objective: This study aims to investigate the causes of 2-vehicle collisions involving an autonomous vehicle (AV) and a conventional vehicle (CV). Prior research has primarily focused on the causes of crashes from the perspective of AVs, often neglecting the interactions with CVs.

Method: To address this limitation, the study proposes a classification framework for crash causation patterns in 2-vehicle collisions involving an AV and a CV, considering their interactions.

View Article and Find Full Text PDF

Background: Immune checkpoint inhibitors (ICIs) have emerged as the first-line treatment for driver-negative advanced non-small cell lung cancer (NSCLC). However, there is uncertainty regarding the availability and timing of ICI initiation in patients with NSCLC combined with pulmonary tuberculosis (TB). Additionally, the implementation of dual therapy for anti-TB and anti-tumor treatment poses significant challenges in terms of avoiding drug-drug interactions and reducing adverse reactions during clinical diagnosis and treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!